The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Deborah A. Thomas

Department of Leukemia

The University of Texas MD Anderson Cancer Center

Houston

USA

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA. 2000 - 2011
  • Anderson Cancer Ctr., 1515 Holcombe Blvd., Unit 428, Houston, USA. 2007

References

  1. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Thomas, D.A., O'Brien, S., Faderl, S., Manning, J.T., Romaguera, J., Fayad, L., Hagemeister, F., Medeiros, J., Cortes, J., Kantarjian, H. Curr. Hematol. Malig. Rep (2011) [Pubmed]
  2. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Thomas, D.A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J.L., Bueso-Ramos, C., Andreeff, M., Pierce, S., Garris, R., Keating, M.J., Cortes, J., Kantarjian, H.M. J. Clin. Oncol. (2010) [Pubmed]
  3. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Thomas, D., O'Brien, S., Faderl, S., Ravandi, F., Jabbour, E., Pierce, S., Cortes, J., Kantarjian, H. Cancer (2010) [Pubmed]
  4. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Thomas, D.A., O'Brien, S., Jorgensen, J.L., Cortes, J., Faderl, S., Garcia-Manero, G., Verstovsek, S., Koller, C., Pierce, S., Huh, Y., Wierda, W., Keating, M.J., Kantarjian, H.M. Blood (2009) [Pubmed]
  5. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Thomas, D.A., O'Brien, S., Kantarjian, H.M. Hematol. Oncol. Clin. North Am. (2009) [Pubmed]
  6. Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy. Thomas, D.A., Ravandi, F., Keating, M., Kantarjian, H.M. Leuk. Lymphoma (2009) [Pubmed]
  7. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Thomas, D.A., Kantarjian, H.M., Stock, W., Heffner, L.T., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Pierce, S., Lu, B., Deitcher, S.R., O'Brien, S. Cancer (2009) [Pubmed]
  8. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Thomas, D.A. Hematology. Am. Soc. Hematol. Educ. Program (2007) [Pubmed]
  9. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Thomas, D.A., O'Brien, S., Cortes, J., Kantarjian, H. Curr. Hematol. Malig. Rep (2007) [Pubmed]
  10. Monoclonal antibody therapy for hairy cell leukemia. Thomas, D.A., Ravandi, F., Kantarjian, H. Hematol. Oncol. Clin. North Am. (2006) [Pubmed]
  11. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Thomas, D.A., Sarris, A.H., Cortes, J., Faderl, S., O'Brien, S., Giles, F.J., Garcia-Manero, G., Rodriguez, M.A., Cabanillas, F., Kantarjian, H. Cancer (2006) [Pubmed]
  12. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Thomas, D.A., Giles, F.J., Albitar, M., Cortes, J.E., Verstovsek, S., Faderl, S., O'Brien, S.M., Garcia-Manero, G., Keating, M.J., Pierce, S., Zeldis, J., Kantarjian, H.M. Cancer (2006) [Pubmed]
  13. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Thomas, D.A., Faderl, S., Cortes, J., O'Brien, S., Giles, F.J., Kornblau, S.M., Garcia-Manero, G., Keating, M.J., Andreeff, M., Jeha, S., Beran, M., Verstovsek, S., Pierce, S., Letvak, L., Salvado, A., Champlin, R., Talpaz, M., Kantarjian, H. Blood (2004) [Pubmed]
  14. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Thomas, D.A., O'Brien, S., Cortes, J., Giles, F.J., Faderl, S., Verstovsek, S., Ferrajoli, A., Koller, C., Beran, M., Pierce, S., Ha, C.S., Cabanillas, F., Keating, M.J., Kantarjian, H. Blood (2004) [Pubmed]
  15. Rituximab in relapsed or refractory hairy cell leukemia. Thomas, D.A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M.J., Giles, F.J., Cortes, J., Kantarjian, H.M. Blood (2003) [Pubmed]
  16. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Thomas, D.A., Estey, E., Giles, F.J., Faderl, S., Cortes, J., Keating, M., O'Brien, S., Albitar, M., Kantarjian, H. Br. J. Haematol. (2003) [Pubmed]
  17. New agents in the treatment of acute lymphocytic leukaemia. Thomas, D.A., Cortes, J., Kantarjian, H.M. Best. Pract. Res. Clin. Haematol (2002) [Pubmed]
  18. Lymphoblastic lymphoma. Thomas, D.A., Kantarjian, H.M. Hematol. Oncol. Clin. North Am. (2001) [Pubmed]
  19. Antiangiogenic therapy in leukemia. Thomas, D.A., Giles, F.J., Cortes, J., Albitar, M., Kantarjian, H.M. Acta Haematol. (2001) [Pubmed]
  20. Current role of thalidomide in cancer treatment. Thomas, D.A., Kantarjian, H.M. Curr. Opin. Oncol (2000) [Pubmed]
 
WikiGenes - Universities